{"id":"fixed-low-dose-tinzaparin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tinzaparin is derived from unfractionated heparin through chemical depolymerization, resulting in a mixture of polysaccharide chains with molecular weights between 5,000 and 10,000 Da. It potentiates antithrombin III-mediated inhibition of coagulation factors, particularly factor Xa (anti-Xa activity) with some anti-IIa activity. The fixed low-dose formulation is used for thromboprophylaxis in specific clinical settings.","oneSentence":"Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:30:32.806Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis in medical patients"},{"name":"Thromboprophylaxis in surgical patients"}]},"trialDetails":[{"nctId":"NCT06667999","phase":"PHASE4","title":"The Intensive Care Platform Trial","status":"RECRUITING","sponsor":"Anders Perner","startDate":"2025-06-26","conditions":"Intensive Care Patients, Intensive Care Unit Patients, Critical Illness","enrollment":10000},{"nctId":"NCT05625932","phase":"PHASE3","title":"TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Galician Research Group on Digestive Tumors","startDate":"2023-03-02","conditions":"Colorectal Cancer Metastatic, Thromboembolism","enrollment":232},{"nctId":"NCT06818279","phase":"PHASE2, PHASE3","title":"Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-01-31","conditions":"Portal Vein Thrombosis, Liver Cirrhosis","enrollment":120},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04373707","phase":"PHASE4","title":"Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-05-13","conditions":"COVID, Thrombosis, Pulmonary Embolism","enrollment":1000},{"nctId":"NCT05382481","phase":"NA","title":"Anti Xa Monitoring Low Molecular Weight Heparin on Prevention of Venous Thromboembolism","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2022-05-16","conditions":"Venous Thromboembolism","enrollment":858},{"nctId":"NCT04558892","phase":"PHASE2, PHASE3","title":"Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.","status":"TERMINATED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2015-10-01","conditions":"Nephrotic Syndrome","enrollment":65},{"nctId":"NCT01828697","phase":"PHASE4","title":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-04-24","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1110},{"nctId":"NCT04305756","phase":"NA","title":"Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-06-12","conditions":"Thromboembolism, Postpartum DVT, Thrombosis","enrollment":146},{"nctId":"NCT05172115","phase":"PHASE3","title":"Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-12-22","conditions":"Pulmonary Embolism, Pulmonary Thromboembolisms, Embolism, Pulmonary","enrollment":94},{"nctId":"NCT02486666","phase":"PHASE3","title":"Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose","status":"UNKNOWN","sponsor":"Hamilton Health Sciences Corporation","startDate":"2016-03","conditions":"Venous Thromboembolism","enrollment":20},{"nctId":"NCT03251963","phase":"PHASE2","title":"Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients","status":"COMPLETED","sponsor":"University of Utah","startDate":"2017-09-15","conditions":"Venous Thromboembolism, Deep Venous Thrombosis, Surgery","enrollment":131},{"nctId":"NCT03218514","phase":"","title":"Venous Thromboprophylaxis in Bariatric Surgery","status":"COMPLETED","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2014-07","conditions":"Obesity","enrollment":118},{"nctId":"NCT01621243","phase":"PHASE1, PHASE2","title":"M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer","status":"TERMINATED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2012-05","conditions":"Metastatic Pancreatic Cancer","enrollment":128},{"nctId":"NCT00182403","phase":"PHASE3","title":"Fixed Dose Heparin Study","status":"COMPLETED","sponsor":"McMaster University","startDate":"1998-09","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":866},{"nctId":"NCT01608347","phase":"PHASE4","title":"Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies","status":"COMPLETED","sponsor":"Omar Mamdouh Shaaban","startDate":"2010-01","conditions":"Recurrent Miscarriage","enrollment":228},{"nctId":"NCT00351663","phase":"PHASE4","title":"The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2007-02","conditions":"Venous Thrombosis, Critical Illness","enrollment":39},{"nctId":"NCT01068795","phase":"NA","title":"Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2009-07","conditions":"Fetal Demise, Fetal Growth Restriction, Preeclampsia","enrollment":144},{"nctId":"NCT02070237","phase":"PHASE1","title":"Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis","status":"COMPLETED","sponsor":"MemorialCare Health System","startDate":"2013-08","conditions":"Obesity, Obesity, Morbid, Pregnancy","enrollment":90},{"nctId":"NCT00522392","phase":"PHASE3","title":"Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":48},{"nctId":"NCT01956955","phase":"PHASE4","title":"Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism","status":"UNKNOWN","sponsor":"Ataturk University","startDate":"2011-01","conditions":"This Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.","enrollment":150},{"nctId":"NCT00932100","phase":"PHASE2","title":"A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Regado Biosciences, Inc.","startDate":"2009-07","conditions":"Acute Coronary Syndrome (ACS)","enrollment":640},{"nctId":"NCT00711308","phase":"PHASE4","title":"Tinzaparin in the Treatment of the Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Complejo Hospitalario Xeral-Calde","startDate":"2005-04","conditions":"Acute Pulmonary Embolism","enrollment":102},{"nctId":"NCT00689520","phase":"PHASE4","title":"Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2002-01","conditions":"Venous Thromboembolism","enrollment":241}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tinzaparin","Innohep"],"phase":"marketed","status":"active","brandName":"Fixed low dose tinzaparin","genericName":"Fixed low dose tinzaparin","companyName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","companyId":"academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboprophylaxis in medical patients, Thromboprophylaxis in surgical patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}